National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedDuan KI, Birger M, Au DH
Health care spending on respiratory diseases in the United States, 1996-2016.
The objectives of this study were to estimate health care spending in the U.S. for 11 respiratory conditions from 1996 to 2016, and to provide an evaluation of factors associated with spending growth and detailed trends. Data was taken from the Institute of Health Metrics and Evaluation's Disease Expenditure Project Database. The results showed that spending on respiratory conditions is high, particularly for chronic conditions like asthma and chronic obstructive pulmonary disease. The authors concluded that these findings suggest that service price and intensity should be a key focus for policymakers who seek to reduce health care spending growth.
AHRQ-funded; HS026369.
Citation: Duan KI, Birger M, Au DH .
Health care spending on respiratory diseases in the United States, 1996-2016.
Am J Respir Crit Care Med 2023 Jan 15; 207(2):183-92. doi: 10.1164/rccm.202202-0294OC..
Keywords: Respiratory Conditions, Healthcare Costs, Asthma, Chronic Conditions
Shaker M, Briggs A, Dbouk A
Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab.
Biologic therapy is a paradigm-shifting management strategy for many patients with asthma and chronic urticaria, but concerns for therapy-associated anaphylaxis may limit access to these therapies for patients unable to travel to medical clinics. The objective of this study was to characterize the cost-effectiveness of in-clinic versus at-home biologic therapy with omalizumab and mepolizumab.
AHRQ-funded; HS024599.
Citation: Shaker M, Briggs A, Dbouk A .
Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab.
J Allergy Clin Immunol Pract 2020 Feb;8(2):565-72. doi: 10.1016/j.jaip.2019.09.037..
Keywords: Medication, Healthcare Costs, Asthma, Respiratory Conditions, Chronic Conditions